Analysis of patents on anti-gout therapies issued in China

Bibliography

• Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516
   PubMed Web of Science ®Google Scholar
• Poon SH, Hall HA, Zimmermann B. Approach to the treatment of hyperuricemia. Med Health R I 2009;92:359-62
   PubMedGoogle Scholar
• Dubchak N, Falasca GF. New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis 2010;3:145-66
   PubMedGoogle Scholar
• Scire CA, Manara M, Cimmino MA. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 2013;15:R101
   PubMed Web of Science ®Google Scholar
• Chen JH, Pan WH, Hsu CC, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 2013;65:133-40
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5
   PubMed Web of Science ®Google Scholar
• Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011;13:39
   PubMed Web of Science ®Google Scholar
• Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6
   PubMed Web of Science ®Google Scholar
• Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis 2009;68:1728-33
   PubMed Web of Science ®Google Scholar
• Grobner W, Walter-Sack I. Treatment of hyperuricemia and gout. Med Monatsschr Pharm 2005;28:159-64
   PubMedGoogle Scholar
• Kumar R, Darpan Sharma S, et al. Xanthine oxidase inhibitors: a patent survey. Expert Opin Ther Pat 2011;21:1071-80
   PubMed Web of Science ®Google Scholar
• Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011;377:165-77
   PubMed Web of Science ®Google Scholar
• Becker MA, Kisicki J, Khosravan et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-16
   PubMed Web of Science ®Google Scholar
• Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007;1:69-75
   PubMedGoogle Scholar
• Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis 2012;3:271-86
   PubMedGoogle Scholar
• Liu YF, Xu SH. Research progress of Chinese medicine treatment of gout. Chin Western Med 2012;4:44-7
   Google Scholar
• Fu DH, Zhang XQ, Liu ZQ, et al. Progress in treatment of acute gouty arthritis by traditional Chinese medicine. World J Integr Tradit Western Med 2013;8:204-6
   Google Scholar
• Li HC, Wen CP, Xie ZJ, et al. Literature research of traditional Chinese medical prescriptions of gout in lntermission and chronic phase. Chin Arch Tradit Chin Med 2013;31:252-5
   Google Scholar
• Yuan HY, He M, Ou N. Meta-analysis on clinical therapeutic Effects of TCM on Gout. Chin Arch Tradit Chin Med 2011;29:666-70
   Google Scholar
• Wang L. Intellectual property protection in China. Int Info Libr Rev 2004;36:253-61
   Google Scholar
• Zhan P, Lin T, Lin XY. Recent advancesin novel non-purine selective inhibitors of xanthine oxidase for the treatment of hyperuricemia and gout. Chin J Med Chem 2012;22:403-15
   Google Scholar
• Lee YH, Song GG. Pathway analysis of genome-wide association studies on uric acid concentrations. Hum Immunol 2012;73:805-10
   PubMed Web of Science ®Google Scholar
• Li J. Formula of traditional chinese medicine. China Press of Traditional Chinese Medicine, Beijing; 2006
   Google Scholar
• Jia W L. Forty-two patients with acute gouty arthritis treated by zhitongrushen decoction. Shaanxi J Tradit Chin 2010;31:440-1
   Google Scholar
• Huang LJ, Chen YS. Professor YANG Zhen-guo Zhubai Tongfeng Soup treat Cure Gout 52 cases. J Pract Tradit Chin Intern Med 2011;25:9-10
   Google Scholar
• Li CR, Li DL, Zhou JG, et al. Clinical and experimental study on the effect of complex gout capsule on gout. Lishizhen Med Mater Med Res 2009;20:1914-15
   Google Scholar
• Yang CQ, Cao KG. Clinical observation on treating 30 cases of acute gouty arthritis by gout mixture. China J Tradit Chin Med Pharm 2006;21:474-5
   Google Scholar
• Zhang J. Treatment of gout, hyperuricemia and hyperlipidemia drugs and preparation methods. CN200410052357. 0; 2004
   Google Scholar
• Zhang XH, Lv WY. A drug and preparation for the treatment of gout. CN201010266469. 1; 2010
   Google Scholar
• Zhou GS. Gout pill. CN201110115642. 2; 2011
   Google Scholar
• Zhang H, Gao F, Xiao L. Qingxiao Zhitong powder on the treatment of 50 cases of gouty arthritis. Chin J Inform Tradit Chin Med 2009;16:60
   Google Scholar
• Yan CP. Ointment and preparation methods for the treatment of gout. CN201110103763. 2; 2011
   Google Scholar
• Zhu Q. Topical preparations of Chinese medicine and its preparation method for the treatment of gout. CN200410040457.1; 2004
   Google Scholar
• Wang ZH. Traditional Chinese medicine wine for external use the treatment of gout. CN200410036755.3; 2004
   Google Scholar
• Li XX. A kind of oral traditional Chinese medicine combination for the treatment of gout. CN01010261882.9; 2010
   Google Scholar
• You DS. New use of the traditional Chinese medicine water willow. CN200610010739.6; 2006
   Google Scholar
• Yuan HY, Ou N, Wang LB, et al. Gnetum effective part preparation method and application in preparation for anti- gout drug. CN200910032924.9; 2009
   Google Scholar
• Ai S, Xu W, Wu T, et al. Methods the anti-inflammatory effective parts extracted from Capparis spinosa. CN200310113957.9; 2003
   Google Scholar
• Zhao J, Zhao XQ. The use of steroid saponins compounds and their derivatives in the preparation of drug for treatment of purine metabolic disorders. CN200910094378.1; 2009
   Google Scholar
• Xia DZ, Zhang Y, Lv GY. Research progress of hyperuricemia and gout in prevention of flavonoids compounds. Chin Pharm J 2009;44:721-3
   Google Scholar
• Huo RH, Li LF, Guo SY, et al. An application of flavone in the preparation of excretion uricosuric drugs. CN200510085043.5; 2005
   Google Scholar
• Qiu ZD, Qu XB, Shui DJ, et al. Corn silk extract and preparation method and application in preparation for treating gout drug. CN200810051485.1; 2008
   Google Scholar
• Chen HS, Qiao LM, Lin JG, et al. Celery seed flavonoids and coumarins compounds application in the preparation drug for the prevention and treating of anti-gout. CN200710062800.6; 2007
   Google Scholar
• Kong LD, Yang C, Bao JW, et al. Mulberry extract, extraction methods and uses. CN02113004.3; 2002
   Google Scholar
• Zhang Y, Lu BY, Wu XQ, et al. The application of the extracts from the plum tree(non fruit). CN200610118773.5; 2006
   Google Scholar
• Wen RL. Phloridzin in the preparation of the application of hyperuricemia drug treatment. CN201010246209.8; 2010
   Google Scholar
• Wang SH, Chen CS, Huang SH, et al. Hydrophilic ester-bearing chlorogenic acid binds to a novel domain to inhibit xanthine oxidase. Planta Med 2009;75:1237-40
   PubMed Web of Science ®Google Scholar
• Zhao Y, Bai H. A class of cinnamon alcohol derivatives, its preparation method and drug use. CN200910142064.4; 2009
   Google Scholar
• Murata K, Nakao K, Hirata N, et al. Hydroxychavicol: a potent xanthine oxidase inhibitor obtained from the leaves of betel, Piper betle. J Nat Med 2009;63:355-9
   PubMed Web of Science ®Google Scholar
• Zhu JX, Wang Y, Kong LD, et al. Effeets Biota orientalis extraet and its flavonoid constituents,quercetin and rutin on serum uric acid levelsin noxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activies in mouse liver. Erhnopharmacol 2004;93:133-40
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu JX, Kongt LD, et al. Administration of procyanidins from grape seeds reduces serum uric acid levels and dcereases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice. Basic Clin Pharmacol Toxicol 2004;95:232-7
   Google Scholar
• Zhao Y, Gong JM, Liu GM. A class silybin derivatives of the E ring substituted and its preparation. CN201010117295.2; 2010
   Google Scholar
• Huang KX, Wang F, Li XA, et al. Ethyl malonyl silibinin derivatives were used for the preparation of antioxidant drug use. CN200910096290.3; 2009
   Google Scholar
• Zhao Y, Wang F, Liu GM, et al. A method for preparing A ring to replace silybin ether and their medical application. CN200910099042.4; 2009
   Google Scholar
• Yang DJ, Zhong GY, Xu JH, et al. The application of puerarin and its derivatives in pharmacy. CN200810069880.2; 2008
   Google Scholar
• Bai L, Song LY, Lei T, et al. Quercetin dimers flavonoids was used to prepare antioxidant drug use. CN201010181800.X; 2010
   Google Scholar
• Fen FJ, Wang WY, Yu JP, et al. A kind for prevention and treatment of gout and hyperuricemia drugs. CN200610091089.2; 2006
   Google Scholar
• Shen L, Ji HF. Insights into the inhibition of xanthine oxidase by curcumin. Bioorg Med Chem Lett 2009;19:5990-3
   PubMed Web of Science ®Google Scholar
• Shui Q, Wang XM, Wang ZF, et al. 2-(3-cyano-4- isobutyl-phenyl)-4- methyl-5- thiazole formic acid crystal form and preparation method. CN200610030935.X0; 2006
   Google Scholar
• Shui Q, Wang XM, Wang ZF, et al. Febuxostat crystal form and preparation methods. CN200710047268.0; 2007
   Google Scholar
• Shui Q, Wang XM, Wang ZF, et al. 2-(3-cyano-4- isobutyl-phenyl)-4- methyl-5- thiazole formic acid crystal form and preparation method. CN201010003140.6.X 0; 2006
   Google Scholar
• Zhang JQ, Wang N, Zhao CJ, et al. Urate oxidase lipid nanoparticles and preparation methods. CN200910103269.1; 2009
   Google Scholar
• Li JM, Hao B, Yang JT, et al. The treatment of acute gout colchicine transdermal absorption patch and its preparation method. CN200710057506.6; 2007
   Google Scholar
• Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species generation: a process in critical need of reevaluation. Redox Biol 2013;1:353-8
   PubMed Web of Science ®Google Scholar
• Yu KH. Febuxostat: a novel non-purine selective in-hibitor of xanthine oxidase for the treatment of hype-ruricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007;1:69-75
   PubMedGoogle Scholar
• Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-55
   PubMed Web of Science ®Google Scholar
• Shiguan ZG, Shenben HS, Fuchen J, et al. 1- phenyl pyrazole compounds and pharmaceutical applications. CN97180548.2; 1997
   Google Scholar
• Wang S, Yan J, Wang J, et al. Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors. Eur J Med Chem 2010;45:2663-70
   PubMed Web of Science ®Google Scholar
• Kawakami M, Tokoro M, Ikeda K, et al. Therapeutic agent for hypertension. WO2008126772A1; 2008
   Google Scholar
• MIyata J, Yokota M, Naito R, et al. 2-phenyl-thiophene derivative. WO2006022375A1; 2006
   Google Scholar
• Miyata J, Naito R, Kawakami M, et al. 2-phenyl pyridine derivatives. CN200580028792.2; 2005
   Google Scholar
• Nakamura H, Kaneda S, Sato T, et al. New 1,2,4 - triazole compounds. CN02819276.1; 2002
   Google Scholar
• Ishibuchi S, Morimoto H, Inoue H, et al. 1-phenyl pyrazole compounds and pharmaceutical applications. CN97180548.2; 1997
   Google Scholar
• Zhao Y, Wang F, Bai H. 3-(3-nitro-4-hydroxy)-ethyl acrylate inhibition of xanthine oxidase medicinal use. CN200610090013.8; 2006
   Google Scholar
• Qi YM, Jie Q, Zhang FM. Inhibit the xanthine oxidase activity of aromatic nitrile thiazole derivatives, preparation method and use. CN200810121654.4; 2008
   Google Scholar
• Feng MS, Cao YZ, Yao QZ, et al. 2-aryl-thiazole derivatives and pharmaceutical compositions thereof. CN200910033852.X; 2009
   Google Scholar
• Wang CL, Li YD, Chen MH, et al. Arachidonic acid as xanthine oxidase inhibitor use and in the preparation of the treatment for hyperuricemia or gout drug. CN201110008531.1; 2011
   Google Scholar
• Li L, Zhu HJ, Zhu YF, et al. Compound 3,5,2,4 - tetrahydroxy chalcone as preparation for the prevention and control of hyperuricemia and gout. CN201010144406.9; 2010
   Google Scholar
• Zhu X, Jiang XM, Zhang YG, et al. The preparation method of the Febuxostat intermediates. CN200910035373.1; 2009
   Google Scholar
• Zhou QG. The preparation method of the febuxostat intermediates. CN201010543350.4; 2010
   Google Scholar
• Beedkar SD, Khobragade CN, Chobe SS, et al. Novel thiazolo-pyrazolyl derivatives as xanthine oxidase inhibitors and free radical scavengers. Int J Biol Macromol 2012;50:947-56
   PubMed Web of Science ®Google Scholar
• Jansen TL, Reinders MK, Van-Roon EN, et al. Benzbromarone with drawn from the European market: another case of "absence of evidence is evidence of absence"? Clin Exp Rheumatol 2004;22:651
   PubMed Web of Science ®Google Scholar
• Xu WH, Zhang SP, Xiao JY, et al. Clinical observation of losartan in treatment of hypertension complicated with hyperuricemia. Foreign Med Sci (Section of Cardiovascular Disease) 2001;28:41-3
   Google Scholar
• Wempe MF, Jutabha P, Quade B. Developing potent human uric acid transporter 1 (hURAT1) inhibitors. J Med Chem 2011;54(8):2701-13
   PubMed Web of Science ®Google Scholar
• O'Neil JD, Sharma S, Ramachandran A. Tetrazole compounds for reducing uric acid. CN200980115547.3; 2009
   Google Scholar
• Wang SJ, Zhang TJ. 2-ethyl-3-(4- hydroxyl) benzoyl benzofuran compounds,compositions and methods of preparation. CN201210167867.7; 2012
   Google Scholar
• Fraisse L, Bonnet MC, De Farcy JP, et al. A colorimetric 96-well microtiter plate assay for the determination of urate oxidase activity and its kinetic parameters. Anal Biochem 2002;309(2):173-9
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee DH, Kho CW, et al. Transthyretin-related proteins function to facilitate the hydrolysis of 5-hydroxyisourate, the end product of the uricase reaction. FEBS Lett 2005;579(21):4769-74
   PubMed Web of Science ®Google Scholar
• Oda M, Satta Y, Takenaka O, et al. Two independent mutational evente in the loss of urate oxidase during hominoid evolution. Mol Biol Evol 2002;5:640-53
   Google Scholar
• Christen P, Peacock WC, Christen AE, et al. Urate oxidase in drimate dhylogenesis. Eur J Biochem 1970;1:3-5
   Google Scholar
• Perez-Ruiz F, Sundy J, Krishnan E, et al. Efficacy and safety of Lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol refractory gout patients: rando-mized, double-blind, placebo-controlled, phase 2b study. Arthritis Rheum 2011;63:398-9
   Google Scholar
• Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704
   PubMed Web of Science ®Google Scholar
• Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 2007;9:258-64
   PubMedGoogle Scholar
• Liu GA, Yang Z, Lin QH, et al. Pegylated uricoxidase compound, its preparation method, its preparation and Application. CN200710068506.6; 2007
   Google Scholar
• Fan K, Zhang C, Ma XF. Humanized recombinant uricase and its mutants. CN200910191240.3; 2009
   Google Scholar
• Wu YZ, Xu MB, Chen Y. A method for preparation of restructuring candida urate oxidase. CN03109150.4; 2003
   Google Scholar
• Ensor CM, Clark MA, Holtzberg FW. PEG modification of urate oxidase. CN02819387.3; 2002
   Google Scholar
• Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation. In vitro and vivo studies on the roles of tumor necrosis factor α and interleukin-1. Arthritis Rheum 1997;40(5):955-65
   PubMedGoogle Scholar
• So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9(2):28
   PubMed Web of Science ®Google Scholar
• Ottosen ER, Rachlin S. As interleukin and TNF inhibitors amino diacetone. CN98802830.1; 1998
   Google Scholar
• Han SH. New uses of bacterial lipopolysaccharide. CN200910226694.X; 2009
   Google Scholar
• Miao ZM, Li CG, Wang YL. 5′-AMP for the treatment of gouty arthritis. CN201010261859.X; 2010
   Google Scholar
• Gao YX, Han JX, Li HZ. Novel 2-oxo heterocyclic compounds and containing the compounds pharmaceutical compositions. CN200480013231.0; 2004
   Google Scholar
• Gaul M, Searle LL, Rentzeperis D. As estrogen related receptor modulator to replace the phenoxy N - alkylation of thiazolidinedione. CN200880015361.6; 2008
   Google Scholar
• End DW, Cools MLL, Van Wauwe JPF. Farnesyl protein transferase inhibitors for treating arthropathies. CN99808311.9; 1999
   Google Scholar
• Bombardelli E, Fontana G. Colchicine nucleoside analogues. CN200480015665.4; 2004
   Google Scholar
• Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia 2010 Edition(a). China Press of Traditional Chinese Medicine, Beijing; 2010
   Google Scholar
• Liu GM. Combinations of synthetic compounds and traditional Chinese medicines for treating gout. CN200710077710.4; 2007
   Google Scholar
• Li CP. A medicinal combination for the treatment of gout. CN200910016369.0; 2009
   Google Scholar
• Gao XM. Science of Chinese materia medica [M]. China Press of Traditional Chinese Medicine, Beijing; 2006
   Google Scholar
• Li L, Chen ZH. New use of mangiferin compounds. CN200810058019.6; 2008
   Google Scholar
• Wu HP, Ha TZ, Zhang Z, et al. The application of Caulis Polygoni Multiflori. CN201010214582.5; 2010
   Google Scholar
• Wu HP, Chen MJ, Xu TT, et al. Inhibition of alpha glucosidase and xanthine oxidase activity of extracts from traditional Chinese medicine, preparation method and application. CN201010219609.X; 2010
   Google Scholar
• Lian Y, Yang YH, Wang MY. Syringin in the preparation of the application for treatment of acute gout drug. CN201010263542.X; 2010
   Google Scholar
• Wang CL, Qi X, Chen MH. Use vegetable extracts inhibited xanthine oxidase and in the preparation for the prevention and treatment of Hyperuricemia or gout in food applications. CN201110026446.8; 2011
   Google Scholar
• Chen J, Li P, Gao W. Salvianolic acid C application in the preparation of the prevention and treatment of hyperuricemia drugs. CN201210000772.6; 2012
   Google Scholar
• Chen ZH. Leaf extract of Herba Siegesbeckiae, preparation method and application thereof. CN200710170657; 2007
   Google Scholar
• Chen GH. Pandan leaf extract in the treatment of gout and its preparation method. CN200810066408.3; 2008
   Google Scholar
• Zhang TM, Sun XB. Frankincense in preparation for the treatment of gout drug use. CN200510021019.5; 2005
   Google Scholar
• Zhang B, Liu XQ, Sa Y, et al. The new use water extract of chicory. CN200510021019.5; 2005
   Google Scholar
• Zhang B, Liu XQ, Lin ZJ, et al. Chicory or Jerusalem artichoke effective parts and its preparations. CN200910089644.1; 2009
   Google Scholar
• Song Y, Sheng R, Tan J, et al. The new use of Fructus Evodiae Rutaecarpae and its extract. CN201010124121.9; 2010
   Google Scholar
• Yu HW, Ma YR. Pennycress total extraction method and its medicinal use. CN201010503873.6; 2010
   Google Scholar
• Ma Y, Lv GY, Chen SH. Effect of radix puerariae extracts on acute gouty arthritis and its mechanisms. Tradit Chin Drug Res Clin Pharmacol 2011;22:241-4
   Google Scholar
• Lin J C. Analysis and mechanism of Polygonum cuspidatum extract on experimental gout. Asia-Pacific Tradit Med 2012;8:21-2
   Google Scholar
• Hou J P. Effects of Polygonum cuspidatum extract on acute gouty arthritis induced by sodium urate rabbit synovial tissue PPAR-C. Chin J New Drugs Clin Remedies 2010;26:76-9
   Google Scholar
• M Y, Yan HY, Lin M, et al. Effect of extracts of paederia scandens on acute gouty arthritis induced by monosodium urate crystals in rats. China Pharmacy 2008;19:411-14
   Google Scholar
• Deng J G, Zheng Z W, Huang L Q. Study on anti-gout effects of ethanol extract of rhizoma smilax Chinae. Sci Technol Eng 2009;9:1393-4
   Google Scholar
• Li L, Lv M, Fang J D, et al. New method of sulfur chemical phade-analysis. J Wuhan Inst Technol 2012;34:13-15
   Google Scholar
• Liang N, Wang C L, Luo C, et al. Effect of toona sinensis leaves extract against to gout. Acad Periodical Farm Prod Process 2011;7:12-14
   Google Scholar
• Cen ZF, Zhang JP, Li HY, et al. Effects of different extracts of phyllanthus emblica on sodium urate-induced acute gouty arthritis in rats. China Pharmacy 2011;22:4425-7
   Google Scholar
• Xia ZD. Study on the effective fractions from Prunus mume to treat hyperuricemia and gout and their mechanisms. Zhejiang University, Hangzhou; 2010. p. 1-211
   Google Scholar
• Qian Y. Study on traditional Chinese in Anti-gout. Zhejiang University, Hangzhou; 2011. p. 1-107
   Google Scholar
• Cao RZ, Zhang SY, Dai Y, et al. The research of the total coumarin of cortex fraxini reducing the level of uric acid in hyperuricemia mice and its mechanism. Liaoning J Tradit Chin Med 2010;37:362-3
   Google Scholar
• Chien SC, Yang CW, Tseng YH, et al. Lonicera hypoglauca inhibits xanthine oxidase and reduces serum uric acid in mice. Planta Med 2009;75:302-6
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu JX, Kong LD, et al. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice. Basic Clin Pharmacol Toxicol 2004;94:232-7
   PubMed Web of Science ®Google Scholar
• Hou CW, Lee YC, Hung HF, et al. Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity. Am J Chin Med 2012;5:979-91
   Google Scholar
• Yang DJ, Zhong GY, Xu JH, et al. The application of taxol and its derivatives in pharmaceutical. CN200810069882.1; 2008
   Google Scholar
• Le KL, Luo J. (-) (3- trihalomethyl methylphenoxy) (4-halophenyl) acetic acid derivatives application in the treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia. CN00811290.8; 2000
   Google Scholar
• Le KL, Luo J. (-) (3- trihalomethyl methylphenoxy) (4-halophenyl) acetic acid derivatives application in the treatment of hyperuricemia. CN200410011657.4; 2000
   Google Scholar